tbuckley/cabot-search huggingface dataset:
Concise evaluation and therapeutic guidelines for severe periodontitis: A public health perspective
Authors: Jørgen Slots
Journal: Periodontology 2000 (2022)

The main goal of periodontology is to prevent and arrest gingivitis and periodontitis to avoid tooth loss and focal infection of periodontal origin. Periodontal scaling or flap surgery of moderate-to-severe periodontitis have shortcomings, most likely because removal of herpesviruses and bacterial pathogens in deep periodontal lesions and the adjacent inflamed gingiva requires systemic antimicrobial treatment (or gingivectomy). Valacyclovir (1000 mg twice daily on day 1, and 500 mg twice daily on day 2 and on day 3) is a potent anti-herpesvirus agent. Antibiotic combinations against bacterial pathogens include amoxicillin-metronidazole (250 mg of each, thrice daily for 4 days; for systemically healthy adults) and ciprofloxacin-metronidazole (500 mg of each, twice daily for 4 days; for immunosuppressed individuals and patients exposed to contaminated water and poor sanitation). Supportive antiseptic treatment may consist of 0.1%-0.2% sodium hypochlorite (regular household bleach) as cooling spray in ultrasonic scalers, flosser fluid in oral irrigators, and mouthrinse in patient self-care. The anti-infective treatment described here helps control cases of severe periodontitis and constitutes an exceedingly inexpensive alternative to conventional (mechanical) periodontal therapy.
Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)
Authors: Jessica R Schumacher, Heather B Neuman, Menggang Yu, David J Vanness, Yajuan Si, Elizabeth S Burnside, Kathryn J Ruddy, Ann H Partridge, Deborah Schrag, Stephen B Edge, Ying Zhang, Elizabeth A Jacobs, Jeffrey Havlena, Amanda B Francescatti, David P Winchester, Daniel P McKellar, Patricia A Spears, Benjamin D Kozower, George J Chang, Caprice C Greenberg, Karla Ballman, Patrick Gavin, Bettye Green, Jane Perlmutter, Elizabeth Berger, Rinaa Punglia, Ronald Chen, Nicole Brys, Taiwo Adesoye
Journal: JNCI Journal of the National Cancer Institute (2022)

Guidelines for follow-up after locoregional breast cancer treatment recommend imaging for distant metastases only in the presence of patient signs and/or symptoms. However, guidelines have not been updated to reflect advances in imaging, systemic therapy, or the understanding of biological subtype. We assessed the association between mode of distant recurrence detection and survival.In this observational study, a stage-stratified random sample of women with stage II-III breast cancer in 2006-2007 and followed through 2016 was selected, including up to 10 women from each of 1217 Commission on Cancer facilities (n = 10 076). The explanatory variable was mode of recurrence detection (asymptomatic imaging vs signs and/or symptoms). The outcome was time from initial cancer diagnosis to death. Registrars abstracted scan type, intent (cancer-related vs not, asymptomatic surveillance vs not), and recurrence. Data were merged with each patient's National Cancer Database record.Surveillance imaging detected 23.3% (284 of 1220) of distant recurrences (76.7%, 936 of 1220 by signs and/or symptoms). Based on propensity-weighted multivariable Cox proportional hazards models, patients with asymptomatic imaging compared with sign and/or symptom detected recurrences had a lower risk of death if estrogen receptor (ER) and progesterone receptor (PR) negative, HER2 negative (triple negative; hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.54 to 0.99), or HER2 positive (HR = 0.51, 95% CI = 0.33 to 0.80). No association was observed for ER- or PR-positive, HER2-negative (HR = 1.14, 95% CI = 0.91 to 1.44) cancers.Recurrence detection by asymptomatic imaging compared with signs and/or symptoms was associated with lower risk of death for triple-negative and HER2-positive, but not ER- or PR-positive, HER2-negative cancers. A randomized trial is warranted to evaluate imaging surveillance for metastases results in these subgroups.
Tell Them
Authors: Alexander W. Steinberg
Journal: JAMA Neurology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer
Authors: Jinyoung Byun, Younghun Han, Yafang Li, Jun Xia, Erping Long, Jiyeon Choi, Xiangjun Xiao, Meng Zhu, Wen Zhou, Ryan Sun, Yohan Bossé, Zhuoyi Song, Ann Schwartz, Christine Lusk, Thorunn Rafnar, Kari Stefansson, Tongwu Zhang, Wei Zhao, Rowland W. Pettit, Yanhong Liu, Xihao Li, Hufeng Zhou, Kyle M. Walsh, Ivan Gorlov, Olga Gorlova, Dakai Zhu, Susan M. Rosenberg, Susan Pinney, Joan E. Bailey-Wilson, Diptasri Mandal, Mariza de Andrade, Colette Gaba, James C. Willey, Ming You, Marshall Anderson, John K. Wiencke, Demetrius Albanes, Stephan Lam, Adonina Tardon, Chu Chen, Gary Goodman, Stig Bojeson, Hermann Brenner, Maria Teresa Landi, Stephen J. Chanock, Mattias Johansson, Thomas Muley, Angela Risch, H.-Erich Wichmann, Heike Bickeböller, David C. Christiani, Gad Rennert, Susanne Arnold, John K. Field, Sanjay Shete, Loic Le Marchand, Olle Melander, Hans Brunnstrom, Geoffrey Liu, Angeline S. Andrew, Lambertus A. Kiemeney, Hongbing Shen, Shanbeh Zienolddiny, Kjell Grankvist, Mikael Johansson, Neil Caporaso, Angela Cox, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Alpa Patel, Qing Lan, Nathaniel Rothman, Fiona Taylor, Linda Kachuri, John S. Witte, Lori C. Sakoda, Margaret Spitz, Paul Brennan, Xihong Lin, James McKay, Rayjean J. Hung, Christopher I. Amos
Journal: Nature Genetics (2022)
Large-scale genome-wide association study of coronary artery disease in genetically diverse populations
Authors: Catherine Tcheandjieu, Xiang Zhu, Austin T. Hilliard, Shoa L. Clarke, Valerio Napolioni, Shining Ma, Kyung Min Lee, Huaying Fang, Fei Chen, Yingchang Lu, Noah L. Tsao, Sridharan Raghavan, Satoshi Koyama, Bryan R. Gorman, Marijana Vujkovic, Derek Klarin, Michael G. Levin, Nasa Sinnott-Armstrong, Genevieve L. Wojcik, Mary E. Plomondon, Thomas M. Maddox, Stephen W. Waldo, Alexander G. Bick, Saiju Pyarajan, Jie Huang, Rebecca Song, Yuk-Lam Ho, Steven Buyske, Charles Kooperberg, Jeffrey Haessler, Ruth J. F. Loos, Ron Do, Marie Verbanck, Kumardeep Chaudhary, Kari E. North, Christy L. Avery, Mariaelisa Graff, Christopher A. Haiman, Loïc Le Marchand, Lynne R. Wilkens, Joshua C. Bis, Hampton Leonard, Botong Shen, Leslie A. Lange, Ayush Giri, Ozan Dikilitas, Iftikhar J. Kullo, Ian B. Stanaway, Gail P. Jarvik, Adam S. Gordon, Scott Hebbring, Bahram Namjou, Kenneth M. Kaufman, Kaoru Ito, Kazuyoshi Ishigaki, Yoichiro Kamatani, Shefali S. Verma, Marylyn D. Ritchie, Rachel L. Kember, Aris Baras, Luca A. Lotta, Sekar Kathiresan, Elizabeth R. Hauser, Donald R. Miller, Jennifer S. Lee, Danish Saleheen, Peter D. Reaven, Kelly Cho, J. Michael Gaziano, Pradeep Natarajan, Jennifer E. Huffman, Benjamin F. Voight, Daniel J. Rader, Kyong-Mi Chang, Julie A. Lynch, Scott M. Damrauer, Peter W. F. Wilson, Hua Tang, Yan V. Sun, Philip S. Tsao, Christopher J. O’Donnell, Themistocles L. Assimes
Journal: Nature Medicine (2022)
After Roe<i>v</i>Wade: US doctors are harassed, confused, and fearful, and maternal morbidity is increasing
Authors: Janice Hopkins Tanne
Journal: BMJ (2022)

Early last month a pregnant 10 year old girl was brought from her home in Ohio to Indiana for an abortion after she had been raped.It was too late for her to be treated in Ohio, forcing her to travel 175 miles (280 km) across the state boundary. 1 The story drew national and international attention
Estimating National Exposures and Potential Bladder Cancer Cases Associated with Chlorination DBPs in U.S. Drinking Water
Authors: Richard J. Weisman, Austin Heinrich, Frank Letkiewicz, Michael Messner, Kirsten Studer, Lili Wang, Stig Regli
Journal: Environmental Health Perspectives (2022)

Background: Disinfection byproducts (DBPs) in public water systems (PWS) are an unintended consequence resulting from reactions between mostly chlorine-based disinfectants and organic and inorganic compounds in source waters. Epidemiology studies have shown that exposure to DBP (specifically trihalomethanes) was associated with an increased risk of bladder cancer. Objective: Our goal was to characterize the relative differences in exposures and estimated potential bladder cancer risks for people served by different strata of PWS in the United States and to evaluate uncertainties associated with these estimates. Methods: We stratified PWS by source water type (surface vs. groundwater) and population served (large, medium, and small) and calculated population-weighted mean trihalomethane-4 (THM4) concentrations for each stratum. For each stratum, we calculated a population attributable risk (PAR) for bladder cancer using odds ratios derived from published pooled epidemiology estimates as a function of the mean THM4 concentration and the fraction of the total U.S. population served by each stratum of systems. We then applied the stratum-specific PARs to the total annual number of new bladder cancer cases in the U.S. population to estimate bladder cancer incidence in each stratum. Results: Our results show that approximately 8,000 of the 79,000 annual bladder cancer cases in the United States were potentially attributable to DBPs in drinking water systems. The estimated attributable cases vary based on source water type and system size. Approximately 74% of the estimated attributable cases were from surface water systems serving populations of >10,000 people. We also identified several uncertainties that may affect the results from this study, primarily related to the use of THM4 as a surrogate measure for DBPs relevant to bladder cancer. Discussion: Despite significant reductions in exposure over the past several decades, our study suggests that ∼10% of the bladder cancer cases in the United States may still be attributed to exposure to DBPs found in drinking water systems. https://doi.org/10.1289/EHP9985
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Authors: Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, Francesca Bergamo, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Francesca Daniel, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchiò, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Journal: Nature Medicine (2022)

Abstract Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS , BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS / BRAF / EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926 ; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue- RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.
Germline Missense Variants in <i>CDC20</i> Result in Aberrant Mitotic Progression and Familial Cancer
Authors: Owen J. Chen, Ester Castellsagué, Mohamed Moustafa-Kamal, Javad Nadaf, Barbara Rivera, Somayyeh Fahiminiya, Yilin Wang, Isabelle Gamache, Caterina Pacifico, Lai Jiang, Jian Carrot-Zhang, Leora Witkowski, Albert M. Berghuis, Stefan Schönberger, Dominik Schneider, Morten Hillmer, Susanne Bens, Reiner Siebert, Colin J.R. Stewart, Ziguo Zhang, William C.H. Chao, Celia M.T. Greenwood, David Barford, Marc Tischkowitz, Jacek Majewski, William D. Foulkes, Jose G. Teodoro
Journal: Cancer Research (2022)

Abstract CDC20 is a coactivator of the anaphase promoting complex/cyclosome (APC/C) and is essential for mitotic progression. APC/CCDC20 is inhibited by the spindle assembly checkpoint (SAC), which prevents premature separation of sister chromatids and aneuploidy in daughter cells. Although overexpression of CDC20 is common in many cancers, oncogenic mutations have never been identified in humans. Using whole-exome sequencing, we identified heterozygous missense CDC20 variants (L151R and N331K) that segregate with ovarian germ cell tumors in two families. Functional characterization showed these mutants retain APC/C activation activity but have impaired binding to BUBR1, a component of the SAC. Expression of L151R and N331K variants promoted mitotic slippage in HeLa cells and primary skin fibroblasts derived from carriers. Generation of mice carrying the N331K variant using CRISPR-Cas9 showed that, although homozygous N331K mice were nonviable, heterozygotes displayed accelerated oncogenicity of Myc-driven cancers. These findings highlight an unappreciated role for CDC20 variants as tumor-promoting genes. Significance: Two germline CDC20 missense variants that segregate with cancer in two families compromise the spindle assembly checkpoint and lead to aberrant mitotic progression, which could predispose cells to transformation. See related commentary by Villarroya-Beltri and Malumbres, p. 3432
Professor Sir Colin Blakemore FRS, a brilliant force for good within neuroscience and beyond (1944–2022)
Authors: Zoltán Molnár, Anthony J. Hannan
Journal: Nature Neuroscience (2022)

Oxford, in 1979, at the unprecedented tender age of 35 years.In Berkley, Cambridge and Oxford, Colin made many major contributions to our understanding of the organization and development of the visual system 1 .He was also amongst the first to propose that the environment shapes the developing and adult brain 2 .He identified factors that mediate neural plasticity at the molecular, cellular and systems levels 1 .His work defined the periods during which manipulation of sensory input has a lasting effect on sensory perception, thereby defining critical periods for therapeutic interventions.Colin's research on amblyopia eventually led to clinical trials and he continued to work on clinical publications until his death 3 .Many of his seminal research articles have become 'citation classics' 4 , indicating their lasting impact.His major scientific legacies include not only his own extraordinary publication record,
Performance of Control Groups in Early Childhood Health Promotion Trials
Authors: Gloria Santos-Beneit, Rodrigo Fernandez-Jimenez, Amaya de Cos-Gandoy, Patricia Bodega, Raquel Diaz-Munoz, Christopher A. Hill, Alexandra Turco, Maribel Santana, Risa Jaslow, Carlos Peyra, Isabel Carvajal, Valentin Fuster
Journal: Journal of the American College of Cardiology (2022)
Diet-induced inflammation in the anterior paraventricular thalamus induces compulsive sucrose-seeking
Authors: Jingjing Cheng, Xiaolin Ma, Chunlu Li, Rahim Ullah, Xiaoyu Wang, Jianmei Long, Zhenxin Yuan, Shuangshuang Liu, Junfen Fu, Zhong Chen, Yi Shen, Yu-Dong Zhou
Journal: Nature Neuroscience (2022)
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5
Authors: Ye Sun, Kun Yan, Yi Wang, Cheng Xu, Dan Wang, Wei Zhou, Shuning Guo, Yujie Han, Lei Tang, Yanqiu Shao, Shaobo Shan, Qiangfeng C. Zhang, Yujie Tang, Liwei Zhang, Qiaoran Xi
Journal: Nature Cancer (2022)
Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators
Authors: Siyuan Tang, Miguel Garzon Sanz, Oliver Smith, Andreas Krämer, Daniel Egbase, Paul W. Caton, Stefan Knapp, Sam Butterworth
Journal: Acta Pharmaceutica Sinica B (2022)

The cofactor nicotinamide adenine dinucleotide (NAD+) plays a key role in a wide range of physiological processes and maintaining or enhancing NAD+ levels is an established approach to enhancing healthy aging. Recently, several classes of nicotinamide phosphoribosyl transferase (NAMPT) activators have been shown to increase NAD+ levels in vitro and in vivo and to demonstrate beneficial effects in animal models. The best validated of these compounds are structurally related to known urea-type NAMPT inhibitors, however the basis for the switch from inhibitory activity to activation is not well understood. Here we report an evaluation of the structure activity relationships of NAMPT activators by designing, synthesising and testing compounds from other NAMPT ligand chemotypes and mimetics of putative phosphoribosylated adducts of known activators. The results of these studies led us to hypothesise that these activators act via a through-water interaction in the NAMPT active site, resulting in the design of the first known urea-class NAMPT activator that does not utilise a pyridine-like warhead, which shows similar or greater activity as a NAMPT activator in biochemical and cellular assays relative to known analogues.
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
Authors: Sarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, Jun Chu, Elaine Poncio, Mohammad Naqi, Sarthak Gupta, Xinghao Wang, Christopher Oliveira, Dillon Claybaugh, Amit Dey, Shajia Lu, Philip Carlucci, Monica Purmalek, Zerai G Manna, Yinghui Shi, Isabel Ochoa-Navas, Jinguo Chen, Amrita Mukherjee, Kyu Lee Han, Foo Cheung, Galina Koroleva, Yasmine Belkaid, John S Tsang, Richard Apps, Donald E Thomas, Theo Heller, Massimo Gadina, Martin P Playford, Xiaobai Li, Nehal N Mehta, Mariana J Kaplan
Journal: Annals of the Rheumatic Diseases (2022)

Premature cardiovascular events in systemic lupus erythematosus (SLE) contribute to morbidity and mortality, with no effective preventive strategies described to date. Immune dysregulation and metabolic disturbances appear to play prominent roles in the induction of vascular disease in SLE. The peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ suppresses vascular damage and immune dysregulation in murine lupus and improves endothelial dysfunction in other inflammatory diseases. We hypothesised that PGZ could improve vascular dysfunction and cardiometabolic parameters in SLE.
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
Authors: Bartolome Celli, Leonardo Fabbri, Gerard Criner, Fernando J. Martinez, David Mannino, Claus Vogelmeier, Maria Montes de Oca, Alberto Papi, Don D. Sin, MeiLan K. Han, Alvar Agusti
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

"Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision." American Journal of Respiratory and Critical Care Medicine, 206(11), pp. 1317–1325
Temporally divergent regulatory mechanisms govern neuronal diversification and maturation in the mouse and marmoset neocortex
Authors: Wen Yuan, Sai Ma, Juliana R. Brown, Kwanho Kim, Vanessa Murek, Lucia Trastulla, Alexander Meissner, Simona Lodato, Ashwin S. Shetty, Joshua Z. Levin, Jason D. Buenrostro, Michael J. Ziller, Paola Arlotta
Journal: Nature Neuroscience (2022)

Mammalian neocortical neurons span one of the most diverse cell type spectra of any tissue. Cortical neurons are born during embryonic development, and their maturation extends into postnatal life. The regulatory strategies underlying progressive neuronal development and maturation remain unclear. Here we present an integrated single-cell epigenomic and transcriptional analysis of individual mouse and marmoset cortical neuron classes, spanning both early postmitotic stages of identity acquisition and later stages of neuronal plasticity and circuit integration. We found that, in both species, the regulatory strategies controlling early and late stages of pan-neuronal development diverge. Early postmitotic neurons use more widely shared and evolutionarily conserved molecular regulatory programs. In contrast, programs active during later neuronal maturation are more brain- and neuron-specific and more evolutionarily divergent. Our work uncovers a temporal shift in regulatory choices during neuronal diversification and maturation in both mice and marmosets, which likely reflects unique evolutionary constraints on distinct events of neuronal development in the neocortex.
Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders
Authors: Julien Bryois, Daniela Calini, Will Macnair, Lynette Foo, Eduard Urich, Ward Ortmann, Victor Alejandro Iglesias, Suresh Selvaraj, Erik Nutma, Manuel Marzin, Sandra Amor, Anna Williams, Gonçalo Castelo-Branco, Vilas Menon, Philip De Jager, Dheeraj Malhotra
Journal: Nature Neuroscience (2022)
Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function
Authors: Chia-Chen Liu, Jing Zhao, Yuan Fu, Yasuteru Inoue, Yingxue Ren, Yuanxin Chen, Sydney V. Doss, Francis Shue, Suren Jeevaratnam, Ligia Bastea, Na Wang, Yuka A. Martens, Wenhui Qiao, Minghui Wang, Na Zhao, Lin Jia, Yu Yamazaki, Akari Yamazaki, Cassandra L. Rosenberg, Zhen Wang, Dehui Kong, Zonghua Li, Lindsey A. Kuchenbecker, Zachary A. Trottier, Lindsey Felton, Justin Rogers, Zachary S. Quicksall, Cynthia Linares, Joshua Knight, Yixing Chen, Aishe Kurti, Takahisa Kanekiyo, John D. Fryer, Yan W. Asmann, Peter Storz, Xusheng Wang, Junmin Peng, Bin Zhang, Betty Y. S. Kim, Guojun Bu
Journal: Nature Neuroscience (2022)
Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex
Authors: Peter Kokkinos, Charles Faselis, Immanuel Babu Henry Samuel, Andreas Pittaras, Michael Doumas, Rayelynn Murphy, Michael S. Heimall, Xuemei Sui, Jiajia Zhang, Jonathan Myers
Journal: Journal of the American College of Cardiology (2022)